coming holmes

Disgraced Theranos CEO Elizabeth Holmes begins prison sentence just 90 minutes from her hometown of Houston

Elizabeth Holmes, pictured on November 18, is now incarcerated. Photo by Justin Sullivan/Getty Images

A longtime Houstonian is coming home — by way of prison.

Elizabeth Holmes, the disgraced founder of blood-testing startup Theranos, reported to F.P.C. Bryan, on Tuesday, May 30, per multiple news outlets. She is set to serve 11 years and three months in the women's minimum-security prison located some 90 minutes from Houston hometown.

According to the the New York Times, the onetime Tanglewood resident arrived at the prison in a Ford Expedition that appeared to be driven by her mother, Noel Holmes. Her father, Christian Holmes, appeared to be inside.

The Times adds that after some shuffling around, out of the view of the cameras gathered nearby, Holmes entered the facility wearing jeans, glasses and a sweater, and carrying some papers.

Prior to her arrival in Bryan, Holmes, 39, spent Memorial Day weekend with her family on the beach near her oceanfront San Diego home with her partner Billy Evans and their two children, according to the Daily Mail.

As CultureMap previously reported, Holmes was sentenced to more than 11 years in prison on November 18, 2002 in San Jose, California following her conviction in January that year for defrauding Theranos investors.

Actress Amanda Seyfried, who played Holmes in the Hulu series The Dropout, shared her thoughts on the woman she portrayed to great acclaim. “Life’s not fair,” Seyfried noted on Good Morning America on Tuesday, “but in a lot of ways, it’s fair. For her, in particular.”

Thrust into the spotlight as the new face of white-collar, Silicon Valley fraud, Holmes now serves as a warning to those who might consider a similar path, her sentencing judge made clear.

“I suppose we step back and ask what is the pathology of fraud? Is it the refusal to accept responsibility or express contrition in any way?" Judge Edward Davila said during the ruling, according to Yahoo! Finance. "Perhaps that is the cautionary tale that will go forward from this case."

Davila ordered Holmes to turn herself into custody on April 27, 2023.

Specifically, Holmes' sentence is 11 years and three months in prison, with another three years of supervision after release. Additionally, Holmes and her ex-boyfriend and former Theranos COO Ramesh “Sunny” Balwani have been ordered to pay $452 million to their fraud victims.

Once compared to disruptors and innovators Steve Jobs and Bill Gates, Holmes rose to fame by enticing investors with the promise that her Theranos could run hundreds of blood tests via a simple pin prick. Buzz for Theranos grew to the point that Theranos was valued at $9 billion, which made Holmes the world’s first self-made female billionaire.

Yet, after securing more than $900 million in funding, Theranos was proven to be essentially bogus by the Wall Street Journal in 2015.

Facing up to 20 years in prison, a tearful Holmes, who is pregnant, addressed the court. "I stand before you taking responsibility for Theranos," she said, per Yahoo. "I loved Theranos. It was my life’s work. My team meant the world to me. They wanted to make a difference in the world. I am devastated by my failings," she said. "Every day for the past years, I have felt deep pain for the people…those people who believe in us and those patients. I worked so hard to serve. I gave everything I had to try to to build...Theranos. Looking back, there are so many things I would do differently. I tried to realize my dream too quickly."

Holmes is the subject of the aforementioned series, The Dropout, which centers on her early life in Houston, where she grew up in Tanglewood and attended St. John's School. Her father's layoff from Enron is presented as clearly an inciting incident in her life. As The Dropout depicts, Holmes would meet boyfriend/partner Ramesh "Sunny" Balwani, drop out of Stanford, and launch Theranos.

One of the most memorable lines in the miniseries comes when a young Holmes plainly states her goals at a family gathering. "I wanna be a billionaire," she said plainly — a memorable and clearly prophetic statement.

------

This article originally ran on CultureMap.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted